Article
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.
British journal of cancer - 12 Feb 2007
Smalley K S M, Contractor R, Haass N K, Lee J T, Nathanson K L, Medina C A, Flaherty K T, Herlyn M
Abstract excerpt
The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.